Subtype
Neuroendocrine Carcinoma
CI-CAN-00001275NECExplore in graph →
514 active trials12 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001275NECExplore in graph →
Clinical trials
1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (213)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05947500 | Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial | active not recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07129252 | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors(BRAVESST2) | recruiting | Phase 1 / Phase 2 | 150 | Crinetics Pharmaceuticals Inc.INDUSTRY |
| 2 |
| Jul 31, 2026 |
| clinicaltrials |
| NCT07259304 | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | active not recruiting | — | 118 | University of Southern CaliforniaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07402343 | Tarlatamab for SCLC Brain Metastases(T-BRAIN) | recruiting | Phase 2 | 35 | Maastricht University Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07738159 | Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 92 | West China HospitalOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT05957510 | Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment | active not recruiting | Phase 2 | 66 | Guangdong Association of Clinical TrialsOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07339059 | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 35 | Bindu R PotugariOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07713732 | TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | not yet recruiting | Phase 1 | 120 | Treeline Biosciences, Inc.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02595424 | Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | active not recruiting | Phase 2 | 67 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06095583 | Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | recruiting | Phase 3 | 756 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 6 | Jul 27, 2026 | clinicaltrials |
| NCT06992609 | Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.(ALBORAN) | active not recruiting | Phase 3 | 68 | AstraZenecaINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07502300 | A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) | recruiting | Phase 3 | 562 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07728955 | A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy(SCLC) | not yet recruiting | Phase 3 | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT06931626 | Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer | recruiting | Phase 1 | 10 | Nerviano Medical SciencesINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04471974 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 61 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05882058 | DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | recruiting | Phase 2 | 204 | Boehringer IngelheimINDUSTRY | 12 | Jul 23, 2026 | clinicaltrials |
| NCT06437509 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 66 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04877613 | GFRα4 CAR T Cells in MTC Patients | active not recruiting | Phase 1 | 9 | University of PennsylvaniaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)(DeLLphi-301) | active not recruiting | Phase 2 | 222 | AmgenINDUSTRY | 18 | Jul 22, 2026 | clinicaltrials |
| NCT06131840 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 914 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT07253142 | A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer | recruiting | Phase 2 | 120 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07559786 | A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy(ARL-LS-SCLC) | recruiting | Phase 2 | 200 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07712094 | AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer | not yet recruiting | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03043872 | Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)(CASPIAN) | active not recruiting | Phase 3 | 987 | AstraZenecaINDUSTRY | 23 | Jul 16, 2026 | clinicaltrials |
| NCT03892993 | Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers | recruiting | N/A | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05100095 | Hypofractionated Radiation Therapy for Merkel Cell Carcinoma | recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01365169 | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | recruiting | N/A | 590 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05652686 | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | recruiting | Phase 1 / Phase 2 | 203 | Phanes TherapeuticsINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.(MEDIOLA) | active not recruiting | Phase 1 / Phase 2 | 264 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT05691465 | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05747729 | A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05889546 | Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer | recruiting | — | 30 | Indiana UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05628376 | TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO | recruiting | — | 600 | University College, LondonOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 216 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07302347 | A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) | recruiting | Phase 1 / Phase 2 | 20 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07698054 | Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer | not yet recruiting | Phase 2 | 130 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 13, 2026 | clinicaltrials |
| NCT06502977 | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment(DeLLphi-307) | active not recruiting | Phase 2 | 32 | AmgenINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 262 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06103682 | LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)(OBLITERATE) | recruiting | N/A | 100 | University of California, DavisOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07242547 | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients(MERLIN) | recruiting | Phase 2 | 37 | Fundación GECPOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07416695 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC | recruiting | Phase 1 | 138 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04745689 | Study of AZD2811 + Durvalumab in ES-SCLC(TAZMAN) | active not recruiting | Phase 2 | 31 | AstraZenecaINDUSTRY | 4 | Jul 6, 2026 | clinicaltrials |
| NCT07358676 | A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 25 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | recruiting | Phase 2 | 39 | Asrar AlahmadiOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07684170 | Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms | not yet recruiting | Phase 2 | 58 | Compass TherapeuticsINDUSTRY | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07677787 | DLL3-Targeted PET/CT in Small Cell Lung Cancer | recruiting | N/A | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2026source: clinicaltrials